Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib cardiac repolarization study in solid tumors
NCT02009631Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of veliparib in solid tumor (3 arms), sponsored by AbbVie Inc. Primary endpoint: Corrected QT interval calculated by Fridericia's formula at Day 3. Started Nov 2013; status: completed.
02
Drugs
veliparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02009631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009631.